Zobrazeno 1 - 10
of 63
pro vyhledávání: ''
Autor:
Kevin Kalinsky, Vassiliki Karantza, Virginia G. Kaklamani, Claudio Savulsky, Martin Olivo, Gursel Aktan, Peter A. Kaufman, D Xing, A Almonte, Sami Diab, S Misir, Sara M. Tolaney
Publikováno v:
Cancer Research. 78:PD6-13
Background: Eribulin mesylate (ERI), a nontaxane microtubule inhibitor with effects on tumor biology (increased vascular perfusion, reversal of epithelial to mesenchymal transition), is approved as a monotherapy for the treatment of patients (pts) wi
Publikováno v:
Cancer Research. 77:P5-16
BACKGROUND Patients receiving neoadjuvant chemotherapy for breast cancer go on to have surgery regardless of their response. Women with HER-2 positive ER negative tumours (7.5% of all operable breast cancers in the UK) respond so well to neoadjuvant
Publikováno v:
Cancer Research. 77:P3-12
Background: Subcutaneous (sc) trastuzumab has demonstrated non-inferiority to intravenous (iv) trastuzumab and is preferred by patients and providers. Serious administration related reactions (ARRs) such as hypotension, respiratory distress etc. were
Autor:
Paul R. Lockman, Jessica Griffith, Afroz S. Mohammad, Emma L. Dolan, Ute Hoch, R Jagannathan, Chris E. Adkins, Neal Shah
Publikováno v:
Cancer Research. 77:P1-12
BACKGROUND: Brain metastasis of breast cancer is a significant cause of death among women with disseminated breast cancer. Chemotherapy, radiation, and surgery for these metastases provide only minimal benefit with considerable toxicity. The long-act
Autor:
Antonio Antón, Rachel Wuerstlein, Suzette Delaloge, P Button, Carlos Barrios, N Lindegger, Peter M. Ellis, Filippo Montemurro
Publikováno v:
Cancer Research. 77:P1-12
Introduction T-DM1 treatment significantly improved overall survival and had a lower incidence of grade ≥3 adverse events (AEs) vs capecitabine plus lapatinib in patients (pts) with HER2-positive advanced breast cancer (BC) in the EMILIA study, inc
Autor:
S Moran, Ira Gore, D Kendall, Y Manalo, James L. Wade, Pearl Fang, A Kellum, Serena Wong, Andrew T. Chan, Carlos H. Barcenas, Debu Tripathy, V Hansen, Daniel Hunt, Nicholas Iannotti, Ricardo H. Alvarez, E Ibrahim, Elizabeth Olek, Mary Wilkinson, Sara A. Hurvitz, R Ruiz, Richard A. Bryce
Publikováno v:
Cancer Research. 77:P2-11
Background: Neratinib (Puma Biotechnology Inc) is an irreversible pan-HER inhibitor in late-phase development for the treatment of early-stage and metastatic HER2+ BC. Diarrhea, the main toxicity of neratinib, requires active management with loperami
Autor:
Carolien H. Smorenburg, Jml Stouthard, Sabine C. Linn, van Ramshorst, Sjoerd Rodenhuis, Gabe S. Sonke, Tessa G Steenbruggen
Publikováno v:
Cancer Research. 77:P4-21
Introduction: Metastatic breast cancer (MBC) is considered an incurable disease. However, long-term survival is increasingly observed in HER2-positive disease since the introduction of trastuzumab. We explored factors associated with long-term surviv
Autor:
M May, Annie Moisan, Florence Joly, F Marmé, Georgina Meneses-Lorente, J. Cortés, C Schindler, Andrés Cervantes, Jose A. Lopez-Martin, Maria Martinez-Garcia, Francesca Michielin, Iria Gonzalez, Anja Welt, TW Park-Simon, Joan Albanell, Ulrik Lassen, Maurizio Ceppi, Max Hasmann, Andreas Schneeweiss, Martin Weisser, Ian James, Celine Adessi, Wolfgang Jacob, Juan Miguel Cejalvo, Véronique Diéras
Publikováno v:
Cancer Research. 77:P6-11
Background: Inhibition of HER2 and HER3 heterodimerisation is a novel treatment concept in HER2-”low” expressing breast cancer (BC). Lumretuzumab, a glycoengineered monoclonal anti-HER3 antibody, in combination with pertuzumab has demonstrated sy
Autor:
S Peter, B Jose, M Stefan, E-W Jennifer, S Luen, R Salgado, K Astrid, L Sherene, SM Sandra, F Stephen, C Emma
Publikováno v:
Cancer Research. 77:S1-08
Background The presence of stromal TILs (sTILs) is associated with a better prognosis with anti-HER2 therapy in primary HER2-positive BC. The prognostic value of TILs in the advanced setting with pertuzumab-based therapy is unknown. Methods The CLEOP
Autor:
Koch, Maximillian, de Jong, Johannes S, Glatz, Jürgen, Symvoulidis, Panagiotis, Lamberts, Laetitia E, Adams, Arthur, Kranendonk, Mariëtte E G, Terwisscha van Scheltinga, Anton G T, Aichler, Michaela, Jansen, Liesbeth, de Vries, Jakob, Lub-de Hooge, Marjolijn N, Schröder, Carolina P, Jorritsma-Smit, Annelies, Linssen, Matthijs D, de Boer, Esther, van der Vegt, Bert, Nagengast, Wouter B, Elias, Sjoerd G, Oliveira, Sabrina, Witkamp, Arjen, Mali, Willem P Th M, van der Wall, Elsken, Garcia-Allende, Beatriz P, Van Diest, Paul J, de Vries, Elisabeth G, Walch, Axel, van Dam, Gooitzen M, Ntziachristos, Vasilis, Celbiologie, Sub Cell Biology, Pharmaceutics
Publikováno v:
Cancer Research, 77(3). American Association for Cancer Research Inc.
Cancer Research, 77(3), 623. American Association for Cancer Research Inc.
Cancer Research, 77(3), 623-631. AMER ASSOC CANCER RESEARCH
Cancer Res. 77, 623-631 (2017)
Cancer Research, 77(3), 623. American Association for Cancer Research Inc.
Cancer Research, 77(3), 623-631. AMER ASSOC CANCER RESEARCH
Cancer Res. 77, 623-631 (2017)
In vivo tumor labeling with fluorescent agents may assist endoscopic and surgical guidance for cancer therapy as well as create opportunities to directly observe cancer biology in patients. However, malignant and nonmalignant tissues are usually dist